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MutagenicityFour versions of esteriﬁed propoxylated glycerols (EPGs) were evaluated for potential genotoxicity using
a range of in vitro and in vivo assays. H-EPG-05 HR/SO 9:1, H-EPG-05 soyate, and H-EPG-14 soyate were
non-mutagenic in reverse mutation assays (maximum concentration 1000 lg/plate) using Salmonella
typhimurium and Escherichia coli. Heated and unheated H-EPG-05 HR/SO 9:1 and EPG-05 HR/ST 45:55
were likewise non-mutagenic in reverse mutation assays in S. typhimurium strains TA98 and TA100 (max-
imum concentration 5000 lg/plate). H-EPG-05 HR/SO 9:1, H-EPG-05 soyate, and H-EPG-14 soyate, were
devoid of mutagenic activity in a mouse lymphoma assay in L5178Y tk +/ cells (maximum concentra-
tion 200 lg/plate for H-EPG-05 HR/SO 9:1; 100 lg/plate for H-EPG-05 soyate and H-EPG-14 soyate), and
a chromosomal aberration test using human lymphocytes (maximum concentration 50 lg/plate for
H-EPG-05 HR/SO 9:1 and H-EPG-05 soyate; 60 lg/plate for H-EPG-14 soyate). All assays were conducted
with and without metabolic activation. Additionally, H-EPG-05 HR/SO 9:1, H-EPG-05 soyate, and H-EPG-
14 soyate were non-genotoxic in unscheduled DNA synthesis tests in rats (maximum dose 2000 mg/kg).
Based on the results of these assays it was concluded that these versions of EPG were not genotoxic under
any of the conditions of the assays performed.
 2014 Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecom-
mons.org/licenses/by-nc-nd/3.0/).1. Introduction
The potential genotoxicity of four versions of EPG1 was evalu-
ated in the following series of standardized studies: bacterial reverse
mutation (Ames) assay; in vitro mouse lymphoma TK+/ gene muta-
tion assay; in vitro mammalian chromosomal aberration test; and
unscheduled DNA synthesis (UDS) test with mammalian liver cells
in vivo/ex vivo. The bacterial reverse mutation assay alone (with Sal-
monella typhimurium strains TA98 and TA100) was used to screen
heated versions of EPG that might be used for frying and baking.
2. Materials and methods
This series of studies was sponsored by ARCO Chemical Com-
pany, Newton Square, Pennsylvania, and conducted at CovanceLaboratories, Inc. (formerly Corning Hazelton, Inc.) facilities in
North Yorkshire, England, Madison, Wisconsin (USA), and Vienna,
Virginia (USA) at various times between March, 1992 and January,
1993, except for studies of heated and unheated EPG, which were
conducted at between December, 1994 and June, 1995. The studies
were performed in compliance with the principles of Good Labora-
tory Practice (GLP) regulations of one or more of the following:
United Kingdom; United States Food and Drug Administration
(FDA); Organization for Economic Cooperation and Development
(OECD); and Japanese Ministry of Agriculture, Forestry and Fisher-
ies (MAFF).
2.1. EPG
The EPG versions tested were: H-EPG-05 HR/SO 9:1 (Lot #
753489, unless otherwise speciﬁed); H-EPG-05 soyate (Lot #
753568); H-EPG-14 soyate (Lot # 753569); and EPG-05 HR/ST
45:55. Each EPG version was provided by the sponsor.
2.2. Bacterial reverse mutation assay (S. typhimurium and Escherichia
coli)
The bacterial mutagenicity (Ames) assay using standard plate
incorporation and preincubation methods was used (Ames et al.,
1975; Maron and Ames, 1983; Green and Muriel, 1976). S.
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obtained from the National Collection of Type Cultures (London,
UK). E. coli strains WP2 pKM101 and WP2 uvrA pKM101 were
obtained from the Cancer Research Unit, University of York (York,
UK) and Glaxo Group Research Ltd. (Greenford, UK), respectively.
The study consisted of three independent experiments, a toxic-
ity range-ﬁnding test conducted in strain TA100 only, and two
mutation assays. EPG (H-EPG-05 HR/SO 9:1; H-EPG-05 soyate; H-
EPG-14 soyate; EPG-05 HR/ST 45:55) was tested in triplicate in
the presence and absence of the postmitochondrial fraction of
the liver homogenates (S9) from Sprague–Dawley rats pre-treated
with Aroclor 1254 (Batch 0367, Molecular Toxicology, Inc., Annap-
olis, MD). The results of the range-ﬁnding test (data not shown)
showed no toxic effect at concentrations of 8–5000 lg/plate, but
precipitation of the test material was evident at 1000 and
5000 lg/plate. EPG was therefore tested at concentrations of 1.6,
8, 40, 200 and 1000 lg/plate in Experiment 1. Since these treat-
ments were nontoxic, treatments in the presence of S9 in Experi-
ment 2 included a preincubation step. Additionally, a narrower
range of concentrations (62.5, 125, 250, 500 and 1000 lg/plate)
was used to examine those most likely to elicit a mutagenic
response. Negative or solvent (acetone) and positive controls were
included in quintuplicate and triplicate, respectively, with and
without S9 mix. Positive control chemicals consisted of: 2-nitroﬂu-
orene (2NF, Koch-Light, Haverhill, UK); sodium azide (NaN3, Sigma
Chemical Co., Poole, UK); 9-aminoacridine (AAC, Koch-Light,
Haverhill, UK); 4-nitroquinoline 1-oxide (NQO, Fluka Chemicals
Ltd., Glossop, UK); and 2-aminoanthracene (AAN, Sigma Chemical
Co., Poole, UK).
Assay responses were considered positive if: (1) the assay was
valid (the assay was considered valid if: (i) the mean negative con-
trol counts fell within the range of the laboratory’s historical con-
trol data; (ii) positive control chemicals induced clear increases in
revertant numbers in appropriate strains, and an active S9 prepa-
ration where appropriate; and (iii) no more than 5% of the plates
were lost due to contamination or some other unforeseen event);
(2) a signiﬁcant response from Dunnett’s test (p 6 0.01) was
observed and the data set showed a signiﬁcant dose correlation
(p 6 0.05); (3) the positive responses described in (2) were
reproducible.
2.3. Bacterial reverse mutation assay (S. typhimurium)
A modiﬁed (preincubation) Ames assay (Yahagi et al., 1975;
Maron and Ames, 1983) was used to assess the mutagenic poten-
tial of: (1) H-EPG-05 HR/SO 9:1, heated (Lot # 850364) and
unheated (Lot # 850324) vs. palm/rapeseed oil (60:40), heated
(Lot # 850363) and unheated (Lot # 850362); and (2) EPG-05
HR/ST 45:55, heated (Lot # 900407) and unheated (Lot #
850308) vs. cottonseed oil, heated (Lot # 900406) and unheated
(Lot # 900405).
S. typhimurium histidine strains TA98 and TA100 were incu-
bated with the test materials at concentrations of 100, 250, 500,
1000, 2500, and 5000 lg/plate, in the presence and absence of S9
mix (Batch 0544, Molecular Toxicology, Inc., Annapolis, MD). Tester
strains were received directly from Dr. Bruce Ames (Department of
Biochemistry, University of California, Berkeley).
Vehicle (acetone) and positive controls were tested concur-
rently in the presence and absence of S9. Positive control chemicals
consisted of: AAN (Sigma Chemical Co., Poole, UK); 2NF, Aldrich
Chemical Co., Gillingham, UK); and NaN3 (Sigma Chemical Co.,
Poole, UK).
EPG (all concentrations), vehicle control, and positive controls
were plated in triplicate. Speciﬁcally, 0.5 mL of S9 mix (metabolic
activation) or 0.5 mL of 0.1 M phosphate buffer (no metabolic acti-
vation) was added to a test tube. Bacterial tester strains (100 lL)and the appropriate volume of vehicle or test article was then
added and incubated for 20 min at 37 C. After incubation, 2.0 mL
of top agar was added to the mixture and poured onto a minimal
bottom agar plate. Positive control articles were plated using a
50 lL plating volume. The plates were incubated for 48 h at
37 C, then evaluated for the number of revertant colonies.
The study consisted of two independent tests, the initial muta-
genicity assay and a conﬁrmatory assay (Experiments 1 and 2,
respectively). A response was considered positive if the test mate-
rial produced a concentration-related increase of at least twofold
in the mean number of revertants per plate in at least one of the
tester strains over the appropriate vehicle control value.
2.4. In vitro mouse lymphoma TK+/ gene mutation assay
The ability of EPG (H-EPG-05 HR/SO 9:1; H-EPG-05 soyate; H-
EPG-14 soyate) to induce mutation at the thymidine kinase (tk)
locus in L5178Y tk +/mouse lymphoma cells (American Type Cul-
ture Collection) was examined, in accordance with Organization
for Economic Co-operation and Development (OECD) guideline
476, using the procedures described by Cole et al. (1983, 1990).
The study consisted of three independent tests: a cytotoxicity
range-ﬁnding test and two mutation assays. Each assay was con-
ducted in the absence and presence of S9 (Batch 0544, Molecular
Toxicology, Inc., Annapolis, MD).
Immediately prior to the assay, EPG was dissolved in analytical-
grade acetone (with warming at 37 C) to give the required concen-
tration. Further dilutions were made using analytical-grade ace-
tone (Batch number MC 1370 in range-ﬁnding and Experiment 1;
K 17184406 in Experiment 2). Test chemical solutions were pro-
tected from light and used within approximately 1.5 h of initial for-
mulation. Positive controls, NQO (Fluka Chemicals Ltd., Glossop,
UK) and benzo (a) pyrene (Aldrich Chemical Co., Gillingham, UK),
were used for non-activation and activation assays, respectively.
Negative controls were comprised of treatments with the solvent
acetone diluted 100-fold in the treatment medium. The basic med-
ium was RPMI 1640 supplemented with gentamycin (100 lg/mL),
fungizone (2.5 lg/mL), and pluronic (0.5 mg/mL) (RPMI A). The
growth medium (RPMI 10) was RPMI A supplemented with 10%
(v/v) heat-inactivated horse serum. The cloning medium (RPMI
20) was RPMI 1640 supplemented with gentamycin (100 lg/mL),
fungizone (2.5 lg/mL), and 20% (v/v) heat-inactivated horse serum.
Cofactor solutions, with and without S9, were also added to the
cultures (1–19 mL of cell culture).
The mouse lymphoma cells were suspended in 50-mL centri-
fuge tubes containing at least 107 cells in 18.8 mL of RPMI 5 (cells
in RPMI 10 diluted with RPMI A to give a ﬁnal concentration of 5%
serum). In the range-ﬁnding assay (data not shown), cells were
exposed to EPG at concentrations ranging from 3.125 to 100 lg/
mL. Single cultures were prepared and positive controls were not
included. Solvent or test material (0.2 mL), and S9 mix or
150 mM KCl were added to the cultures. After 3 h of shaking at
37 C, tubes were centrifuged (200g for 5 min), cells were washed
with phosphate buffered saline and resuspended in 20 mL RPMI/
tube. Cell concentrations were adjusted to 8 cells/mL and, for each
dose, 0.2 mL was plated into 32 mL wells. The plates were incu-
bated at 37 C in a humidiﬁed incubator gassed with 5% (v/v)
CO2 in air for 12 days. Wells containing viable clones were identi-
ﬁed and counted.
For Experiments 1 and 2, the assays generally followed the
range-ﬁnding assay procedures. Duplicate cell cultures (single for
positive control) were exposed to H-EPG-05 HR/SO 9:1 at concen-
trations ranging from 12.5 to 200 lg/mL; H-EPG-05 soyate and H-
EPG-14 soyate were tested at 25–100 lg/mL. Following treatment,
cell densities were determined using a Coulter counter and the
concentrations adjusted to 2  105/mL. An aliquot of each cell
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well plates at 0.2 mL/well (averaging 1.6 cells/well). The plates
were incubated at 37 C in a humidiﬁed incubator gassed with
5% (v/v) CO2 in air for 12 days. Wells containing viable clones were
identiﬁed by eye using background illumination and counted.
The remaining cell suspensions were cultured for 2 days to
allow for expression of the TKmutation. At the end of the expres-
sion period, the cell suspension of cultures was diluted to 104 cells/
mL. An aliquot of each cell suspension was transferred to 96-well
plates for incubation to evaluate viability, in the same manner as
described above for evaluation of survival. 5-Triﬂuorothymidine
(TFT) was added to the remaining cell suspensions at 3 lg/mL for
the selection of mutant colonies. The cell suspension was trans-
ferred to 96-well plates at 0.2 mL/well (2  103 cells/well) and
incubated for 11–12 days. Following the incubation period, wells
containing clones were identiﬁed as above and counted for calcu-
lation of mutant frequency (MF).
The statistical signiﬁcance of mutant frequencies was assessed
according to the UKEMS guidelines (Robinson et al., 1990). The
validity of the assay was based on the following criteria: (1) the
mutant frequencies in the negative (solvent) control cultures fell
within the normal range; and (2) at least one concentration of each
of the positive control chemicals induced a clear increase in
mutant frequency. The test substance was considered to be muta-
genic if: (1) the assay was valid; (2) at least one concentration of
the test substance resulted in signiﬁcantly greater mutant fre-
quency than that of the negative control; (3) there was a signiﬁcant
dose-relationship as indicated by the linear trend analysis; and (4)
the effects described above were reproducible.2.5. In vitro mammalian chromosomal aberration test
Independent experiments (Experiments 1 and 2) were con-
ducted to evaluate the potential of EPG (H-EPG-05 HR/SO 9:1; H-
EPG-05 soyate; H-EPG-14 soyate) to induce chromosome aberra-
tions in cultured human lymphocytes (male and female donors).
The experiments were performed in accordance with OECD guide-
line 473, in duplicate (quadruplicate for solvent controls).
Whole heparinized blood (0.4 mL) from two healthy donors was
added to sterile disposable centrifuge tubes with 9 mL Hepes-buf-
fered RPMI medium containing 20% (v/v) fetal calf serum and
50 lg/mL gentamycin. The medium contained phytohemaggluti-
nin A (37.5 lL per mL of culture) to stimulate lymphocyte prolifer-
ation. The cultures were incubated at 37 C for 48 h with
continuous rocking.
Prepared cultures were treated (in the presence and absence of
S9 mix) with: EPG dissolved in acetone; solvent control (acetone);
untreated control (culture medium); or positive controls (NQO;
cyclophosphamide, CPA) in duplicate (solvent control in quadrupli-
cate). H-EPG-05 HR/SO 9:1 and H-EPG-05 soyate were tested at
concentrations ranging from 0.99 to 50 lg/mL (0.05 and 0.1 mL,
respectively); H-EPG-14 soyate was tested at concentrations
between 1.186 and 60 lg/mL (0.1 mL). The untreated control (cul-
ture medium) was used at 0.1 and 0.05 mL; NQO at 2.5 and 5 lg/
mL; and CPA at 25 lg/mL. Cultures treated in the presence of met-
abolic activation received 0.5 mL S9 per 9.5 mL of cell culture; cul-
tures treated in the absence of metabolic activation received
0.5 mL 150 mM KCl.
The male and female donor cultures were exposed to each sub-
stance under the following conditions: exposure for 3 h with S9
(pulse treatment) and without S9, followed by a 17-h recovery per-
iod before harvesting; exposure for 3 h with S9, followed by a 41-h
recovery period before harvesting; or exposure for 20 or 44 h with
no S9 and no recovery period. Before the recovery period, culturesreceiving pulse treatments were pelleted (200g, 10 min), washed
twice with sterile saline, and resuspended in fresh medium (fetal
calf serum + gentamycin).
Colchicine (1 lg/mL ﬁnal concentration) was added approxi-
mately 1.5 h prior to harvesting. Cells were then harvested, swol-
len in 0.075 M KCl, and ﬁxed in methanol:glacial acetic acid (3:1
v/v). The ﬁxative was changed by centrifugation (200g, 10 min)
and resuspension. This procedure was repeated twice (centrifuging
at 1250g, 2–3 min) until the supernatants were clear. Lympho-
cytes were kept in ﬁxative in the refrigerator (approximately
4 C) before slides were prepared; slides were not made on the
day of harvest to ensure cells were adequately ﬁxed. Cells were
pelleted and resuspended in fresh ﬁxative (approximately
0.2 mL). Several drops of 45% (v/v) aqueous acetic acid were added
to each suspension to enhance spreading, and several drops of sus-
pension were then dropped on to clean microscope slides which
had been dipped in water. After the slides dried, cells were stained
for 5 min in Giemsa (4% v/v) in pH 6.8 buffer.
Based on the effect of EPG on mitotic index (MI), three consec-
utive concentrations were chosen for the chromosome aberration
analysis. One-hundred metaphases from each culture (200 meta-
phases per concentration) were analyzed, and aberrations were
classiﬁed according to the scheme described by ISCN (1985). Aber-
rant cells in each culture were categorized as follows: (1) cells with
structural aberrations including gaps; (2) cells with structural
aberrations excluding gaps; and (3) polyploidy, endoreduplicated
or hyperdiploid cells. The proportions of cells in categories 1 and
3 were compared to historical control values; statistically signiﬁ-
cant differences between the test and negative control in the pro-
portion of cells in category 2 was determined using Fisher’s exact
test. The response is this assay was considered positive if: (1) sta-
tistically signiﬁcant increases in the proportion of structurally
aberrant cells (without gaps) occurred at one or more concentra-
tions; (2) the proportion of aberrant cells at such data points
exceeded the normal range; and (3) the results were conﬁrmed
in the second independent experiment.2.6. Unscheduled DNA synthesis (UDS) test with mammalian liver cells
in vivo/ex vivo
Three independent experiments, a range-ﬁnding and two main
studies (Experiments 1 and 2), were conducted according to the
procedure detailed by Ashby et al. (1985) as modiﬁed from the ori-
ginal assay developed by Mirsalis and Butterworth (1980) to assess
the potential of EPG (H-EPG-05 HR/SO 9:1; H-EPG-05 soyate; H-
EPG-14 soyate) to induce unscheduled DNA synthesis (UDS) in
liver cells isolated from rats exposed orally.
Wistar rats (6/group), purchased from Charles River UK Ltd.
(Margate, UK), received a single oral (gavage) dose of: corn oil
(vehicle control); 632.5 or 2000 mg/kg bw of EPG dissolved in corn
oil; 75 mg/kg bw of 2-acetamidoﬂuorene (2-AAF) suspended in
corn oil (positive control); or 10 mg/kg bw dimethylnitrosamine
(DMN) dissolved in puriﬁed water (positive control). The EPG dose
of 2000 mg/kg was selected as the upper dose level, based on the
results of a range-ﬁnding experiment, which showed no mortality
or toxicity at 2000 mg/kg bw (5 male rats; single oral dose; 3-day
observation period). All compounds were administered at 10 mL/
kg. In both Experiment 1 and 2, dosing was carried out at two time
points approximately 2.5 h apart, treating 3 animals per dose
group at each time point.
Approximately 12–14 h (Experiment 1) or 2–4 h (Experiment 2)
after dosing, animals were anesthetized with ether. The liver of
each animal was isolated and washed free of blood with calcium-
free buffer (pH 7.4; 150 mM NaCl; 3.73 mM NaHCO3; 4.84 mM
Table 1b
H-EPG-05 HR/SO 9:1 performance in the reverse mutation (Ames) assay (Experiment 2).
S. typhimurium E. coli
TA98 TA100 TA1535 TA1537 WP2 pKM101 WP2 uvrA pKM101
S9 +S9 S9 +S9 S9 +S9 S9 +S9 S9 +S9 S9 +S9
Negative control (Acetone) 24.4 ± 5.6 25.3 ± 3.2 105.8 ± 8.7 125.4 ± 16.1 18.8 ± 2.4 24.8 ± 2.9 14.8 ± 2.8 13.6 ± 4.9 56.6 ± 1.9 78.2 ± 3.9 145.0 ± 20.9 126.2 ± 20.0
62.5 lg/plate 19.3 ± 1.5 25.7 ± 11.0 107.0 ± 1.0 148.0 ± 15.7 16.0 ± 3.6 23.7 ± 7.5 16.0 ± 5.0 11.3 ± 4.2 57.0 ± 10.5 72.0 ± 9.5 132.0 ± 41.8 140.7 ± 18.6
125 lg/plate 20.7 ± 7.6 23.3 ± 1.5 93.7 ± 2.5 135.7 ± 28.0 23.3 ± 7.2 14.5 ± 2.1 12.0 ± 0.0 9.7 ± 2.1 59.0 ± 8.7 68.0 ± 14.0 151.0 ± 11.1 147.7 ± 11.0
250 lg/plate 21.7 ± 6.7 25.0 ± 5.6 106.0 ± 17.0 146.7 ± 27.2 15.0 ± 2.0 21.7 ± 7.4 14.7 ± 4.9 12.3 ± 1.5 65.0 ± 19.9 60.0 ± 3.5 142.3 ± 13.4 115.3 ± 15.5
500 lg/plate 31.3 ± 5.1 30.7 ± 6.8 109.7 ± 12.2 143.7 ± 6.4 17.0 ± 2.6 26.7 ± 2.1 12.0 ± 3.5 13.0 ± 3.6 61.7 ± 5.0 63.3 ± 10.0 148.3 ± 15.3 160.5 ± 48.8
1000 lg/plate 26.7 ± 3.1 28.3 ± 0.6 109.7 ± 15.3 155.7 ± 6.5 17.0 ± 1.0 24.7 ± 7.0 14.0 ± 1.7 17.7 ± 1.5 57.7 ± 3.2 59.7 ± 2.5 158.0 ± 6.0 147.7 ± 25.0
Positive control 1740.0 ± 86.8b 1306.7 ± 7.6a 775.7 ± 153.0c – 500.0 ± 32.0c – 657.0 ± 18.2d – 265.0 ± 65.8e – 1221.3 ± 260.2e 370.3 ± 25.6a
Values represent mean revertants per plate ± SD, unless otherwise speciﬁed. Plating aliquot: 50 lL.
a 2-Aminoanthracene (AAN).
b 2-Nitroﬂuorene (2NF).
c Sodium azide (NaN3).
d 9-Aminocridine (AAC).
e 4-Nitroquinoline 1-oxide (NQO).
Table 1a
H-EPG-05 HR/SO 9:1 performance in the reverse mutation (Ames) assay (Experiment 1).
S. typhimurium E. coli
TA98 TA100 TA1535 TA1537 WP2 pKM101 WP2 uvrA pKM101
S9 +S9 S9 +S9 S9 +S9 S9 +S9 S9 +S9 S9 +S9
Negative control (Acetone) 24.8 ± 4.8 18.2 ± 6.7 97.0 ± 14.2 141.4 ± 6.6 13.4 ± 4.0 19.6 ± 4.6 14.6 ± 3.2 16.4 ± 7.1 54.4 ± 7.6 77.6 ± 17.0 130.6 ± 30.2 177.6 ± 30.0
1.6 lg/plate 29.7 ± 1.5 14.3 ± 3.2 – – 20.3 ± 3.1 18.7 ± 4.6 12.5 ± 2.1 13.3 ± 4.0 47.7 ± 8.4 81.7 ± 4.0 142.0 ± 21.4 171.0 ± 13.9
8 lg/plate 26.7 ± 2.5 21.0 ± 2.0 104.3 ± 9.5 162.3 ± 19.7 12.0 ± 3.6 20.3 ± 3.2 12.3 ± 1.2 13.0 ± 5.3 58.0 ± 9.5 92.0 ± 4.6 135.0 ± 11.4 163.7 ± 18.5
40 lg/plate 37.7 ± 2.5 16.3 ± 5.5 96.0 ± 8.7 142.7 ± 3.8 17.3 ± 6.1 20.7 ± 1.2 18.7 ± 3.5 14.7 ± 1.5 64.3 ± 6.5 69.0 ± 10.1 134.0 ± 30.8 155.0 ± 17.3
200 lg/plate 21.7 ± 5.8 16.0 ± 2.0 117.0 ± 28.9 157.0 ± 8.5 13.7 ± 4.0 20.3 ± 2.1 13.0 ± 3.6 10.3 ± 1.5 59.7 ± 4.2 78.3 ± 9.0 147.7 ± 7.6 132.3 ± 14.7
1000 lg/plate 16.0 ± 7.8 19.3 ± 1.2 113.0 ± 11.1 166.7 ± 23.1 21.3 ± 6.1 18.0 ± 3.6 12.7 ± 3.1 16.0 ± 2.8 54.3 ± 4.9 67.7 ± 3.5 146.3 ± 20.1 134.3 ± 22.0
Positive control 1243.0 ± 171.5b 1032.7 ± 178.0a 625.7 ± 12.2c 1827.0 ± 323.7a 522.7 ± 37.4c – 1246.3 ± 266.4d – 133.7 ± 27.4e – 1071.0 ± 254.9e 821.3 ± 46.3a
Values represent mean revertants per plate ± SD, unless otherwise speciﬁed. Plating aliquot: 50 lL.
a 2-Aminoanthracene (AAN).
b 2-Nitroﬂuorene (2NF).
c Sodium azide (NaN3).
d 9-Aminocridine (AAC).
e 4-Nitroquinoline 1-oxide (NQO).
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Table 2a
H-EPG-05 soyate performance in the reverse mutation (Ames) assay (Experiment 1).
S. typhimurium E. coli
TA98 TA100 TA1535 TA1537 WP2 pKM101 WP2 uvrA pKM101
S9 +S9 S9 +S9 S9 +S9 S9 +S9 S9 +S9 S9 +S9
Negative control (Acetone) 19.8 ± 5.1 36.2 ± 3.2 101.2 ± 10.2 141.4 ± 11.5 13.0 ± 3.6 23.0 ± 4.3 14.0 ± 5.0 16.4 ± 1.9 52.2 ± 13.6 79.4 ± 10.4 130.2 ± 15.5 178.2 ± 14.1
1.6 lg/plate 20.3 ± 4.0 34.7 ± 1.2 – – 15.7 ± 4.9 25.0 ± 7.5 9.0 ± 1.0 13.7 ± 3.8 59.3 ± 3.5 78.7 ± 7.6 133.0 ± 28.4 167.0 ± 21.3
8 lg/plate 20.0 ± 7.0 32.7 ± 8.1 105.7 ± 10.1 129.7 ± 11.9 13.7 ± 0.6 22.0 ± 5.3 12.7 ± 3.5 15.3 ± 4.7 53.7 ± 5.5 81.3 ± 1.2 131.3 ± 6.4 160.3 ± 11.8
40 lg/plate 20.3 ± 3.1 31.7 ± 5.1 116.0 ± 12.3 151.3 ± 18.0 11.0 ± 7.5 20.0 ± 5.3 10.3 ± 3.1 14.3 ± 2.5 54.3 ± 16.3 70.7 ± 6.7 128.0 ± 2.6 160.7 ± 6.1
200 lg/plate 21.3 ± 1.5 32.0 ± 6.1 102.3 ± 6.1 140.3 ± 9.0 12.0 ± 2.0 24.3 ± 2.1 11.7 ± 4.5 11.3 ± 4.2 59.7 ± 9.1 77.7 ± 28.1 128.0 ± 15.4 147.7 ± 7.4
1000 lg/plate 20.7 ± 1.5 27.7 ± 8.1 105.7 ± 7.0 97.3 ± 12.1 13.0 ± 1.0 19.0 ± 3.5 8.0 ± 1.0 11.3 ± 4.2 51.0 ± 1.0 64.7 ± 9.0 139.3 ± 28.9 155.3 ± 17.0
Positive control 1255 ± 323.9b 1697.0 ± 141.1a 744.0 ± 53.8c 2208.0 ± 42.3a 461.3 ± 39.0c – 365.7 ± 19.7d – 134.3 ± 6.5e – 1551.0 ± 124.0e 961.3 ± 4.5a
Values represent mean revertants per plate ± SD, unless otherwise speciﬁed. Plating aliquot: 50 lL.
a 2-Aminoanthracene (AAN).
b 2-Nitroﬂuorene (2NF).
c Sodium azide (NaN3).
d 9-Aminocridine (AAC).
e 4-Nitroquinoline 1-oxide (NQO).
Table 2b
H-EPG-05 soyate performance in the reverse mutation (Ames) assay (Experiment 2).
S. typhimurium E. coli
TA98 TA100 TA1535 TA1537 WP2 pKM101 WP2 uvrA pKM101
S9 +S9 S9 +S9 S9 +S9 S9 +S9 S9 +S9 S9 +S9
Negative control (Acetone) 16.2 ± 3.8 23.8 ± 7.2 111.0 ± 6.5 101.6 ± 15.6 9.6 ± 3.8 16.8 ± 4.9 12.2 ± 1.8 13.2 ± 3.1 60.4 ± 10.9 76.8 ± 6.9 148.4 ± 10.0 123.6 ± 7.9
62.5 lg/plate 18.7 ± 5.7 23.7 ± 3.5 105.7 ± 8.7 109.7 ± 9.6 10.3 ± 2.1 17.0 ± 4.4 13.3 ± 3.8 10.3 ± 1.5 58.7 ± 7.5 78.3 ± 13.6 130.7 ± 2.5 121.7 ± 7.4
125 lg/plate 14.7 ± 1.5 22.0 ± 3.0 101.3 ± 6.7 118.3 ± 11.7 11.3 ± 3.1 15.0 ± 2.0 14.3 ± 2.5 15.0 ± 1.1 59.0 ± 8.2 75.3 ± 9.5 135.3 ± 11.0 128.3 ± 9.2
250 lg/plate 15.0 ± 4.0 19.0 ± 4.6 89.3 ± 11.0 105.7 ± 10.6 11.7 ± 1.5 16.7 ± 5.7 16.3 ± 4.0 13.7 ± 1.2 55.3 ± 4.0 79.0 ± 14.5 126.7 ± 13.6 119.3 ± 5.5
500 lg/plate 17.3 ± 3.1 27.0 ± 0.0 84.3 ± 1.5 122.7 ± 14.2 12.3 ± 3.5 23.3 ± 3.1 13.3 ± 0.6 18.0 ± 7.0 57.7 ± 5.8 71.3 ± 15.3 139.7 ± 14.0 116.3 ± 12.7
1000 lg/plate 17.0 ± 2.6 27.0 ± 2.6 111.0 ± 17.3 97.3 ± 11.7 14.7 ± 3.5 21.0 ± 5.0 13.0 ± 2.0 16.7 ± 3.8 58.7 ± 11.0 59.7 ± 9.0 143.0 ± 1.0 119.0 ± 13.5
Positive control 629.7 ± 141.9b 953.0 ± 59.0a 591.0 ± 54.7c – 580.0 ± 117.5c – 511.0 ± 22.9d – 313.7 ± 6.7e – 1282.7 ± 90.0e 710.7 ± 21.6a
Values represent mean revertants per plate ± SD, unless otherwise speciﬁed. Plating aliquot: 50 lL.
a 2-Aminoanthracene (AAN).
b 2-Nitroﬂuorene (2NF).
c Sodium azide (NaN3).
d 9-Aminocridine (AAC).
e 4-Nitroquinoline 1-oxide (NQO).
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Table 3a
H-EPG-14 soyate performance in the reverse mutation (Ames) assay (Experiment 1).
S. typhimurium E. coli
TA98 TA100 TA1535 TA1537 WP2 pKM101 WP2 uvrA pKM101
S9 +S9 S9 +S9 S9 +S9 S9 +S9 S9 +S9 S9 +S9
Negative control (Acetone) 19.8 ± 5.1 36.2 ± 3.2 101.2 ± 10.2 141.4 ± 11.5 13.0 ± 3.6 23.0 ± 4.3 14.0 ± 5.0 16.4 ± 1.9 52.2 ± 13.6 79.4 ± 10.4 130.2 ± 15.5 178.2 ± 14.1
1.6 lg/plate 20.7 ± 3.8 33.3 ± 8.4 – – 14.0 ± 4.4 18.0 ± 3.0 13.7 ± 3.1 11.3 ± 5.7 57.3 ± 5.7 83.3 ± 6.7 130.7 ± 5.5 184.0 ± 20.1
8 lg/plate 21.0 ± 6.6 31.7 ± 8.5 107.3 ± 6.1 128.0 ± 10.8 18.3 ± 7.2 13.7 ± 3.1 10.7 ± 5.9 12.7 ± 4.5 53.3 ± 5.8 80.0 ± 10.1 152.3 ± 7.5 163.3 ± 19.9
40 lg/plate 22.3 ± 1.5 30.0 ± 3.6 95.3 ± 11.7 120.3 ± 7.0 18.0 ± 7.0 16.7 ± 2.3 10.0 ± 2.6 12.3 ± 1.5 49.0 ± 3.5 73.0 ± 6.2 139.7 ± 3.8 177.0 ± 23.1
200 lg/plate 21.3 ± 3.1 26.3 ± 15.7 99.0 ± 25.2 154.3 ± 4.6 13.0 ± 3.5 14.7 ± 1.5 10.7 ± 2.5 11.0 ± 4.4 55.7 ± 10.4 79.0 ± 5.0 139.7 ± 22.5 150.0 ± 13.0
1000 lg/plate 18.7 ± 5.7 32.7 ± 6.7 93.3 ± 12.9 121.3 ± 19.5 9.0 ± 1.0 16.3 ± 5.0 7.3 ± 2.1 9.3 ± 4.0 49.7 ± 5.7 85.7 ± 3.5 134.7 ± 14.6 164.7 ± 10.8
Positive control 1255 ± 323.9b 1697.0 ± 141.1a 744.0 ± 53.8c 2208.0 ± 42.3a 461.3 ± 39.0c – 365.7 ± 19.7d – 134.3 ± 6.5e – 1551.0 ± 124.0e 961.3 ± 4.5a
Values represent mean revertants per plate ± SD, unless otherwise speciﬁed. Plating aliquot: 50 lL.
a 2-Aminoanthracene (AAN).
b 2-Nitroﬂuorene (2NF).
c Sodium azide (NaN3).
d 9-Aminocridine (AAC).
e 4-Nitroquinoline 1-oxide (NQO).
Table 3b
H-EPG-14 soyate performance in the reverse mutation (Ames) assay (Experiment 2).
S. typhimurium E. coli
TA98 TA100 TA1535 TA1537 WP2 pKM101 WP2 uvrA pKM101
S9 +S9 S9 +S9 S9 +S9 S9 +S9 S9 +S9 S9 +S9
Negative control (Acetone) 16.2 ± 3.8 23.8 ± 7.2 111.0 ± 6.5 101.6 ± 15.6 9.6 ± 3.8 16.8 ± 4.9 12.2 ± 1.8 13.2 ± 3.1 60.4 ± 10.9 76.8 ± 6.9 148.4 ± 10.0 123.6 ± 7.9
62.5 lg/plate 19.0 ± 9.6 21.0 ± 4.6 94.3 ± 2.5 118.7 ± 12.0 9.3 ± 0.6 17.0 ± 1.0 14.0 ± 1.7 11.3 ± 2.9 57.3 ± 3.1 72.3 ± 4.2 138.3 ± 18.4 117.3 ± 16.8
125 lg/plate 15.0 ± 1.0 22.3 ± 4.2 99.7 ± 17.0 125.7 ± 18.9 10.3 ± 1.5 12.0 ± 6.2 12.3 ± 1.5 14.0 ± 2.8 51.3 ± 11.2 87.7 ± 2.3 133.7 ± 12.1 111.3 ± 9.1
250 lg/plate 16.3 ± 4.2 25.0 ± 5.0 96.3 ± 11.2 105.7 ± 1.2 10.3 ± 3.5 14.3 ± 3.5 11.7 ± 5.0 15.7 ± 2.5 61.7 ± 3.5 86.0 ± 10.5 139.0 ± 6.6 106.7 ± 16.1
500 lg/plate 13.7 ± 1.5 16.0 ± 2.6 96.3 ± 25.4 103.0 ± 15.1 10.0 ± 3.6 19.7 ± 4.0 17.0 ± 1.7 11.0 ± 4.0 57.3 ± 6.0 79.0 ± 16.5 126.0 ± 14.4 113.7 ± 12.4
1000 lg/plate 22.3 ± 3.5 28.3 ± 3.1 103.7 ± 3.8 91.3 ± 2.5 11.0 ± 3.5 18.3 ± 2.5 12.0 ± 1.7 11.3 ± 2.1 58.0 ± 6.2 76.7 ± 4.2 109.0 ± 17.6 106.7 ± 7.4
Positive control 629.7 ± 141.9b 953.0 ± 59.0a 591.0 ± 54.7c – 580.0 ± 117.5c – 511.0 ± 22.9d – 313.7 ± 6.7e – 1282.7 ± 90.0e 710.7 ± 21.6a
Values represent mean revertants per plate ± SD, unless otherwise speciﬁed. Plating aliquot: 50 lL.
a 2-Aminoanthracene (AAN).
b 2-Nitroﬂuorene (2NF).
c Sodium azide (NaN3).
d 9-Aminocridine (AAC).
e 4-Nitroquinoline 1-oxide (NQO).
S136
D
.H
.Bechtel/R
egulatory
Toxicology
and
Pharm
acology
70
(2014)
S131–
S142
Table 4a
Performance of heated and unheated H-EPG-05 HR/SO 9:1 in the reverse mutation (Ames) assay with two Salmonella typhimurium strains.
Heated Unheated
Experiment 1 Experiment 2 Experiment 1 Experiment 2
TA98 TA100 TA98 TA100 TA98 TA100 TA98 TA100
+S9 S9 +S9 S9 +S9 S9 +S9 S9 +S9 S9 +S9 S9 +S9 S9 +S9 S9
Negative control
(Acetone)
28 ± 1 17 ± 3 117 ± 15 105 ± 5 21 ± 3 15 ± 6 109 ± 3 101 ± 3 28 ± 3 21 ± 3 118 ± 11 106 ± 14 27 ± 4 15 ± 2 70 ± 4 71 ± 5
100 lg/plate 27 ± 5 16 ± 3 139 ± 23 101 ± 8 25 ± 10 17 ± 5 111 ± 15 105 ± 5 26 ± 4 22 ± 6 153 ± 19 98 ± 12 21 ± 4 16 ± 4 63 ± 2 63 ± 2
250 lg/plate 29 ± 2 12 ± 4 127 ± 20 116 ± 14 23 ± 3 20 ± 3 101 ± 14 91 ± 9 31 ± 7 17 ± 6 151 ± 2 120 ± 9 23 ± 4 12 ± 3 74 ± 8 65 ± 2
500 lg/plate 30 ± 11 18 ± 5 119 ± 12 105 ± 14 22 ± 4 15 ± 6 134 ± 7 103 ± 10 28 ± 9 21 ± 6 144 ± 6 104 ± 6 24 ± 3 16 ± 4 84 ± 5 64 ± 2
1000 lg/plate 26 ± 5 16 ± 1 130 ± 12 98 ± 10 24 ± 6 12 ± 4 114 ± 8 96 ± 10 33 ± 7 19 ± 4 137 ± 8 111 ± 9 27 ± 5 22 ± 5 76 ± 10 65 ± 3
2500 lg/plate 30 ± 6 10 ± 2 121 ± 7 92 ± 9 29 ± 9 19 ± 4 128 ± 6 99 ± 5 30 ± 2 21 ± 8 135 ± 12 101 ± 11 22 ± 3 18 ± 6 74 ± 7 62 ± 2
5000 lg/plate 27 ± 4 17 ± 3 131 ± 7 113 ± 9 23 ± 3a 16 ± 6 110 ± 16 85 ± 11 27 ± 2 14 ± 6 140 ± 10 112 ± 10 23 ± 1 19 ± 6 81 ± 1 63 ± 1
Positive control 1153 ± 57a 263 ± 18b 1003 ± 46a 871 ± 2c 1078 ± 106a 258 ± 19b 1016 ± 68a 677 ± 27c 1166 ± 37a 285 ± 35b 1048 ± 60a 695 ± 9c 1065 ± 36a 267 ± 10b 1018 ± 26a 633 ± 26c
Values represent mean revertants per plate ± SD, unless otherwise speciﬁed. Plating aliquot: 50 lL.
a 2-Aminoanthracene (2.5 lg/plate).
b 2-Nitroﬂuorene (1 lg/plate).
c Sodium azide (2 lg/plate).
Table 4b
Performance of heated and unheated palm/rapeseed oil (60:40) in the reverse mutation (Ames) assay with two Salmonella typhimurium strains.
Heated Unheated
Experiment 1 Experiment 2 Experiment 1 Experiment 2
TA98 TA100 TA98 TA100 TA98 TA100 TA98 TA100
+S9 S9 +S9 S9 +S9 S9 +S9 S9 +S9 S9 +S9 S9 +S9 S9 +S9 S9
Negative control (Acetone) 21 ± 5 17 ± 5 118 ± 11 107 ± 9 26 ± 8 20 ± 4 122 ± 12 97 ± 6 27 ± 6 16 ± 4 122 ± 4 106 ± 21 23 ± 2 18 ± 1 114 ± 9 86 ± 8
100 lg/plate 28 ± 8 13 ± 4 113 ± 10 98 ± 6 20 ± 5 18 ± 5 122 ± 7 99 ± 17 23 ± 4 17 ± 3 126 ± 16 94 ± 9 22 ± 7 13 ± 4 106 ± 5 96 ± 4
250 lg/plate 23 ± 3 15 ± 4 115 ± 14 102 ± 15 21 ± 2 15 ± 5 111 ± 17 90 ± 9 24 ± 8 18 ± 3 124 ± 7 105 ± 17 24 ± 1 19 ± 1 110 ± 17 97 ± 4
500 lg/plate 32 ± 8 17 ± 1 138 ± 8 113 ± 11 21 ± 6 17 ± 3 114 ± 17 98 ± 2 22 ± 2 17 ± 2 132 ± 7 109 ± 14 25 ± 6 16 ± 7 106 ± 4 94 ± 19
1000 lg/
plate
30 ± 6 16 ± 4 130 ± 10 91 ± 7 23 ± 5 13 ± 3 120 ± 5 82 ± 12 29 ± 2 15 ± 2 133 ± 13 117 ± 22 30 ± 4 17 ± 3 128 ± 4 85 ± 1
2500 lg/
plate
29 ± 5 16 ± 2 127 ± 13 105 ± 3 25 ± 7 22 ± 6 121 ± 13 94 ± 9 25 ± 6 17 ± 9 123 ± 25 95 ± 16 30 ± 5 15 ± 1 108 ± 11 87 ± 2
5000 lg/
plate
27 ± 7 20 ± 4 119 ± 16 111 ± 9 24 ± 4 17 ± 2 117 ± 13 99 ± 23 31 ± 9 16 ± 8 136 ± 4 110 ± 14 27 ± 5 17 ± 4 115 ± 5 109 ± 8
Positive
control
1038 ± 76a 268 ± 25b 1003 ± 14a 786 ± 24c 1070 ± 99a 240 ± 28b 1074 ± 106a 610 ± 13c 1172 ± 35a 313 ± 18b 1030 ± 17a 794 ± 21c 1017 ± 34a 285 ± 23b 1162 ± 134a 619 ± 21c
Values represent mean revertants per plate ± SD, unless otherwise speciﬁed. Plating aliquot: 50 lL.
a 2-Aminoanthracene (2.5 lg/plate).
b 2-Nitroﬂuorene (1 lg/plate).
c Sodium azide (2 lg/plate).
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Table 5a
Performance of heated and unheated EPG-05 HR/ST 45:55 in the reverse mutation (Ames) assay with two Salmonella typhimurium strains.
Heated Unheated
Experiment 1 Experiment 2 Experiment 1 Experiment 2
TA98 TA100 TA98 TA100 TA98 TA100 TA98 TA100
+S9 S9 +S9 S9 +S9 S9 +S9 S9 +S9 S9 +S9 S9 +S9 S9 +S9 S9
Negative control (Acetone) 21 ± 8 13 ± 6 84 ± 19 77 ± 28 16 ± 1 13 ± 3 100 ± 15 98 ± 13 23 ± 2 12 ± 5 99 ± 5 82 ± 7 20 ± 6 15 ± 6 106 ± 7 95 ± 23
100 lg/plate 18 ± 4 12 ± 1 95 ± 12 81 ± 7 16 ± 3 13 ± 2 100 ± 5 93 ± 13 20 ± 5 12 ± 4 91 ± 13 82 ± 2 23 ± 3 14 ± 5 114 ± 8 90 ± 13
250 lg/plate 19 ± 4 6 ± 5 91 ± 7 78 ± 6 26 ± 4 17 ± 2 123 ± 12 82 ± 4 19 ± 7 14 ± 4 108 ± 5 77 ± 2 19 ± 1 12 ± 6 81 ± 13 81 ± 14
500 lg/plate 16 ± 2 12 ± 2 96 ± 6 66 ± 5 21 ± 5 13 ± 2 112 ± 1 99 ± 7 21 ± 2 10 ± 7 102 ± 10 80 ± 10 18 ± 3 15 ± 3 87 ± 19 84 ± 22
1000 lg/plate 24 ± 1 13 ± 1 88 ± 11 76 ± 5 21 ± 4 17 ± 4 103 ± 6 93 ± 3 22 ± 6 12 ± 4 85 ± 3 78 ± 11 23 ± 7 13 ± 1 120 ± 10 86 ± 15
2500 lg/plate 16 ± 2 9 ± 4 85 ± 14 67 ± 3 19 ± 2 8 ± 2 101 ± 8 92 ± 14 23 ± 3 18 ± 6 99 ± 7 77 ± 7 23 ± 9 15 ± 4 108 ± 11 86 ± 17
5000 lg/plate 21 ± 4 11 ± 6 90 ± 9 64 ± 7 16 ± 3 11 ± 3 96 ± 26 91 ± 26 18 ± 8 9 ± 3 96 ± 19 75 ± 11 14 ± 4 13 ± 2 100 ± 10 96 ± 6
Positive control 1099 ± 29a 205 ± 23b 1077 ± 75a 574 ± 64c 1076 ± 98a 204 ± 21b 1077 ± 21a 703 ± 13c 1067 ± 46a 244 ± 47b 1018 ± 19a 517 ± 41c 1058 ± 48a 254 ± 31b 1097 ± 42a 738 ± 18c
Values represent mean revertants per plate ± SD, unless otherwise speciﬁed. Plating aliquot: 50 lL.
a 2-Aminoanthracene (2.5 lg/plate).
b 2-Nitroﬂuorene (1 lg/plate).
c Sodium azide (2 lg/plate).
Table 5b
Performance of heated and unheated cottonseed oil in the reverse mutation (Ames) assay with two Salmonella typhimurium strains.
Heated Unheated
Experiment 1 Experiment 2 Experiment 1 Experiment 2
TA98 TA100 TA98 TA100 TA98 TA100 TA98 TA100
+S9 S9 +S9 S9 +S9 S9 +S9 S9 +S9 S9 +S9 S9 +S9 S9 +S9 S9
Negative control
(Acetone)
20 ± 5 13 ± 3 86 ± 6 70 ± 8 20 ± 3 15 ± 3 91 ± 9 82 ± 2 25 ± 3 15 ± 5 85 ± 3 68 ± 2 22 ± 7 12 ± 4 83 ± 13 87 ± 7
100 lg/plate 23 ± 3 11 ± 2 86 ± 12 80 ± 4 19 ± 6 12 ± 2 93 ± 6 83 ± 9 27 ± 6 11 ± 1 94 ± 7 75 ± 4 21 ± 3 11 ± 1 90 ± 12 80 ± 5
250 lg/plate 20 ± 4 12 ± 3 101 ± 8 83 ± 5 19 ± 2 11 ± 1 97 ± 15 95 ± 11 22 ± 4 16 ± 4 87 ± 13 77 ± 4 23 ± 8 9 ± 1 85 ± 12 87 ± 2
500 lg/plate 20 ± 5 12 ± 5 90 ± 10 63 ± 13 19 ± 5 13 ± 3 104 ± 14 94 ± 13 24 ± 2 14 ± 1 97 ± 6 72 ± 6 20 ± 8 8 ± 2 100 ± 11 93 ± 6
1000 lg/plate 25 ± 4 7 ± 1 89 ± 3 80 ± 7 19 ± 2 13 ± 5 97 ± 12 81 ± 14 28 ± 11 17 ± 3 88 ± 7 77 ± 8 18 ± 6 10 ± 3 91 ± 15 87 ± 6
2500 lg/plate 21 ± 3 10 ± 2 107 ± 7 71 ± 5 15 ± 3 11 ± 7 88 ± 7 81 ± 14 35 ± 8 14 ± 6 96 ± 3 73 ± 6 15 ± 3 12 ± 4 103 ± 13 91 ± 2
5000 lg/plate 23 ± 4 12 ± 3 97 ± 11 70 ± 8 22 ± 4 9 ± 2 93 ± 9 81 ± 10 30 ± 11 13 ± 4 91 ± 9 72 ± 6 18 ± 1 11 ± 3 97 ± 9 82 ± 12
Positive control 931 ± 96a 218 ± 7b 986 ± 137a 484 ± 18c 1043 ± 7a 188 ± 7b 1018 ± 73a 660 ± 67c 887 ± 31a 204 ± 27b 1028 ± 70a 417 ± 66c 992 ± 45a 200 ± 14b 966 ± 18a 703 ± 32c
Values represent mean revertants per plate ± SD, unless otherwise speciﬁed. Plating aliquot: 50 lL.
a 2-Aminoanthracene (2.5 lg/plate).
b 2-Nitroﬂuorene (1 lg/plate).
c Sodium azide (2 lg/plate).
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Table 7
Performance of H-EPG-05 soyate in the in vitro mouse lymphoma TK+/ gene
mutation assay.
Treatment
(lg/mL)
S9 +S9
%
Relative
survival
Mutant frequency
per 106 viable cells
%
Relative
survival
Mutant
frequency per
106 viable cells
Experiment 1
0 100.0 129.98 100.0 141.68
25 62.5 163.56 84.1 180.24
50 38.7 129.94 74.6 125.33
75 39.6 148.05 86.6 160.82
100 42.1 146.36 87.2 139.09
NQO (0.05) 41.1 406.54 – –
NQO (0.1) 43.0 294.51 – –
BP (2) – – 62.3 745.24
BP (3) – – 48.0 877.35
Experiment 2
0 100.0 133.77 100.0 191.72
25 103.6 178.77 83.1 165.26
50 87.4 145.59 77.9 142.66
75 88.0 117.06 91.9 253.66
100 94.5 138.08 83.7 155.45
NQO (0.05) 95.8 624.42 – –
NQO (0.1) 94.5 452.52 – –
BP (2) – – 69.8 551.96
BP (3) – – 48.4 822.98
Positive controls: NQO (4-nitroquinoline 1-oxide); BP (benzo (a) pyrene).
Table 8
Performance of H-EPG-14 soyate in the in vitro mouse lymphoma TK+/ gene
mutation assay.
Treatment
(lg/mL)
S9 +S9
%
Relative
survival
Mutant frequency
per 106 viable cells
%
Relative
survival
Mutant
frequency per
106 viable cells
Experiment 1
0 100.0 129.98 100.0 141.68
25 55.0 115.40 89.1 150.39
50 46.7 146.18 87.9 172.33
75 45.0 168.13 81.7 160.58
100 47.3 128.05 91.1 155.91
NQO (0.05) 41.1 406.54 – –
NQO (0.1) 43.0 294.51 – –
BP (2) – – 62.3 745.24
BP (3) – – 48.0 877.35
Experiment 2
0 100.0 133.77 100.0 191.72
25 91.2 154.84 81.9 167.37
50 81.3 136.91 83.7 167.27
75 91.2 162.35 75.7 174.18
100 88.6 145.30 89.9 176.07
NQO (0.05) 95.8 624.42 – –
NQO (0.1) 94.5 452.52 – –
BP (2) – – 69.8 551.96
BP (3) – – 48.4 822.98
Positive controls: NQO (4-nitroquinoline 1-oxide); BP (benzo (a) pyrene).
Table 6
Performance of H-EPG-05 HR/SO 9:1 in the in vitro mouse lymphoma TK+/ gene
mutation assay.
Treatment
(lg/mL)
S9 +S9
%
Relative
survival
Mutant frequency
per 106 viable cells
%
Relative
survival
Mutant
frequency per
106 viable cells
Experiment 1
0 100.0 176.51 100.0 166.87
12.5 87.6 200.49 104.4 202.79
25 86.4 219.01 112.2 165.09
50 82.7 173.24 93.1 142.63
100 79.8 166.81 87.4 157.15
200 78.2 217.54 100.0 162.69
NQO (0.05) 79.8 396.40 – –
NQO (0.1) 73.3 805.78 – –
BP (2) – – 74.7 903.51
BP (3) – – 45.0 1424.41
Experiment 2
0 100.0 280.67 100.0 304.30
12.5 109.6 246.03 92.5 329.55
25 116.0 230.31 91.2 280.23
50 95.8 219.91 86.7 229.85
100 82.4 238.98 112.0 256.04
200 101.4 226.15 103.6 225.04
NQO (0.05) 81.8 713.74 – –
NQO (0.1) 48.2 660.51 – –
BP (2) – – 74.3 884.16
BP (3) – – 36.2 1349.53
Positive controls: NQO (4-nitroquinoline 1-oxide); BP (benzo (a) pyrene).
Table 9
Chromosomal aberrations in human peripheral blood lymphocytes exposed in vitro to
H-EPG-05 HR/SO 9:1.
Treatment
(lg/mL)
Cells with aberrations
including gaps
Cells with
aberrations
excluding gaps
Mitotic
index
(mean)
20-h exposure; no recovery; male donor cells; S9
0 (solvent) 3 1 5.2
24.5 2 1 5.0
35 2 1 5.6
50 5 3 4.6
NQO (2.5) 19 18** –
3-h exposure; 17-h recovery; male donor cells; +S9
0 (solvent) 3 2 6.4
24.5 6 1 6.2
35 7 4 6.5
50 6 5 5.6
CPA (25) 24 19** –
20-h exposure; no recovery; female donor cells; S9
0 (solvent) 5 3 5.5
28.13 3 2 4.8
37.5 4 1 5.2
50 6 3 4.5
NQO (5) 9 8** –
3-h exposure; 17-h recovery; female donor cells; +S9
0 (solvent) 2 2 6.4
28.13 2 0 5.9
37.5 2 2 6.3
50 5 5 4.4
CPA (25) 26 22** -
3-h exposure; 17-h recovery; female donor cells; S9
0 (solvent) 2 2 8.1
50 4 3 7.6
44-h exposure; no recovery; female donor cells; S9
0 (solvent) 8 3 4.2
50 4 2 3.6
3-h exposure; 41-h recovery; female donor cells; +S9
0 (solvent) 3 1 5.1
50 3 0 4.9
Total of 200 cells scored per treatment.
NQO: 4-nitroquinoline 1-oxide.
CPA: cyclophosphamide.
** p < 0.001 (These numbers exceed historical negative control ranges.)
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and MgCl2; phenol red indicator 10 lg/mL), followed by perfusion
with buffer (pH 7.4; 142 mM NaCl; 24 mM NaHCO3; 4.37 mM KCl;
1.24 mM KH2PO4; 0.62 mM each MgSO4 and MgCl2; phenol red
indicator 10 lg/mL) supplemented with calcium and collagenase
(50 mg collagenase in 1 mL 769 mM CaCl2 and 10 mL buffer). At
the end of perfusion (7–13 min), the liver was transferred to a ster-
ile plastic petri dish and cut open, and the hepatocytes were teased
out using a combing method. The separated hepatocytes were
Table 10
Chromosomal aberrations in human peripheral blood lymphocytes exposed in vitro to
H-EPG-05 soyate.
Treatment
(lg/mL)
Cells with aberrations
including gaps
Cells with
aberrations
excluding gaps
Mitotic
index
(mean)
20-h exposure; no recovery; in female donor cells; S9
0 (solvent) 6 3 3.0
24.5 4 3 2.9
35 4 1 2.3
50 4 1 3.5
NQO (5) 20 19** –
3-h exposure; 17-h recovery; female donor cells; +S9
0 (solvent) 1 0 5.4
24.5 3 2 4.6
35 1 0 4.9
50 7 4 4.8
CPA (25) 21 18** –
20-h exposure; no recovery; male donor cells; S9
0 (solvent) 2 1 2.2
28.13 1 0 3.2
37.5 3 2 1.9
50 4 1 2.3
NQO (2.5) 16 14** –
3-h exposure; 17-h recovery; male donor cells; +S9
0 (solvent) 2 1 5.8
28.13 1 1 4.9
37.5 3 1 4.5
50 1 0 4.7
CPA (25) 15 12** –
3-h exposure; 17-h recovery; male donor cells; S9
0 (solvent) 0 0 4.9
50 1 1 5.8
44-h exposure; no recovery; male donor cells; S9
0 (solvent) 4 0 3.2
50 1 0 3.4
3-h exposure; 41-h recovery; male donor cells; +S9
0 (solvent) 0 0 4.1
50 0 0 4.6
Total of 200 cells scored per treatment.
NQO: 4-nitroquinoline 1-oxide.
CPA: cyclophosphamide.
** p < 0.001.
Table 11
Chromosomal aberrations in human peripheral blood lymphocytes exposed in vitro to
H-EPG-14 soyate.
Treatment
(lg/mL)
Cells with aberrations
including gaps
Cells with
aberrations
excluding gaps
Mitotic
index
(mean)
20-h exposure; no recovery; female donor cells; S9
0 (solvent) 6 3 3.0
29.4 5 4 3.2
42 1 1 3.2
60 4 1 3.9
NQO (5) 20 19** –
3-h exposure; 17-h recovery; female donor cells; +S9
0 (solvent) 1 0 5.4
29.4 3 1 6.1
42 3 1 5.3
60 2 1 5.3
CPA (25) 21 18** –
20-h exposure; no recovery; male donor cells; S9
0 (solvent) 10 7 1.9
33.75 5 2 2.7
45 7 4 2.3
60 4 2 2.9
NQO (5) 18 17** –
3-h exposure; 17-h recovery; male donor cells; +S9
0 (solvent) 4 4 3.1
33.75 0 0 2.8
45 2 1 4.3
60 3 1 3.6
CPA (25) 19 14** –
3-h exposure; 17-h recovery; male donor cells; S9
0 (solvent) 2 0 4.8
60 9 4 3.9
44-h exposure; no recovery; male donor cells; S9
0 (Solvent) 1 1 2.1
60 1 1 1.9
3-h exposure; 41-h recovery; male donor cells; +S9
0 (Solvent) 3 0 4.3
60 3 1 3.3
Total of 200 cells scored per treatment.
NQO: nitroquinoline 1-oxide.
CPA: cyclophosphamide.
** p < 0.001.
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Complete (WE-C) to a volume of 100 mL. Approximately half
(50 mL) of the suspension was centrifuged (40g, 2–3 min); the
pellet was resuspended and centrifuged three times (40 mL WE-C
twice; 20 mL ﬁnal). A sample (0.5 mL) of the suspension was taken,
diluted with an equal volume of 0.4% (w/v) trypan blue, and the
proportion of viable cells (unstained nuclei) determined using a
hemocytometer. The suspension was diluted to provide 1.5  105
viable cells/mL. Hepatocytes were cultured by adding 3 mL to each
of six wells (6-well plate) containing a 25-mm round plastic cover-
slip, and incubating at 37 C in a 5% CO2 in air (v/v) atmosphere for
approximately 90 min to allow cells to attach.
To radiolabel hepatocyte cultures, medium was removed from
the cells and the monolayer was washed with 2 mL William’s E
medium-Incomplete (WE-I). The medium was then replaced with
WE-I containing 10 lCi/mL [3H] thymidine, incubated for 4 h at
37 C (5% CO2 in air atmosphere), followed by removal of the radio-
label and washing three times with WE-I containing 0.25 mM
unlabeled thymidine. Cultures were then incubated overnight with
3 mL of the same medium.
To prepare for autoradiography, cells were washed with 2 mL
phosphate buffered saline (PBS) then ﬁxed with three changes
(2 mL each) of glacial acetic acid:ethanol (1:3 v/v). The coverslips
were washed four times with distilled water, allowed to dry, and
mounted onto previously labeled microscope slides, cells side up,with DPX. Slides were coated in Ilford K2 liquid emulsion using a
dipping technique. After gelling over ice for 10 min (face-up), slides
were allowed to dry in a light-tight box at room temperature for
approximately 90 min. Slides were then packed in light-tight boxes
containing desiccant, sealed with tape, and refrigerated for
14 days. The emulsion was developed in Kodak D19 developer
and ﬁxed using Ilford Hypam ﬁxer.
For microscopic examination, cells with stained with Mayer’s
hemalum/eosin Y, dehydrated in alcohol, cleared with xylene,
and mounted with coverslips. Grain counting was performed using
a microscope with a video camera connected to a Biotran Colony
counter and a computer programmed for automatic data capture.
Where possible, 100 morphologically normal cells were analyzed
from at least 2 slides. For each slide, the number of cells analyzed
was recorded and for each cell, the grain count over the nucleus
(nuclear grains, NG) and over the cytoplasm (cytoplasmic grains,
CG) was determined; CG counts consisted of the average of number
of grains in three nuclear-equivalent areas of cytoplasm. Based on
these data, the net grains/nucleus (NNG = NG count  CG count)
and percentage of cells in repair (deﬁned as NNGP 5) were calcu-
lated for each slide, animal, and dose group. The population mean
and standard deviation for NNG and for the sub-population of cells
in repair were then calculated. Population average CG counts and
NG counts were also calculated. The assay was considered valid
if the negative control yielded NNG 6 0 (i.e., CG counts exceed
Table 12
Unscheduled DNA synthesis (UDS) in rat hepatocytes following oral exposure to a single dose of H-EPG-05 HR/SO 9:1.
Dose (mg/kg bw) Nuclear grain (NG) count Cytoplasmic
grain (CG) count
Net nuclear grain
(NNG) count
Net grain count of
cells in repair
Percent of cells in repair
(i.e., NNGP 5)
12- to 14-h exposure
0 (corn oil) 2.63 ± 0.73 3.51 ± 0.60 0.9 ± 0.3 0 –
632.5 1.90 ± 0.65 2.81 ± 0.34 0.9 ± 0.7 5.2 ± 0.2 0.6 ± 0.9
2000 2.39 ± 1.00 3.53 ± 0.61 1.1 ± 0.5 7.2 ± 0.0 0.4 ± 0.9
2-AAF (75) 20.45 ± 3.03 2.96 ± 0.68 17.5 ± 2.5 17.8 ± 2.4 97.4 ± l.5
2- to 4-h exposure
0 (Corn oil) 1.89 ± 0.21 2.99 ± 0.29 1.1 ± 0.2 5.8 ± 0.0 0.6 ± l.3
632.5 2.01 ± 0.47 3.03 ± 0.41 1.0 ± 0.2 5.9 ± 0.7 1.4 ± 1.1
2000 1.97 ± 0.62 2.97 ± 0.50 1.0 ± 0.3 5.8 ± 0.2 0.4 ± 0.5
DMN (10) 12.48 ± 1.66 1.28 ± 0.28 11.2 ± 1.4 12.5 ± 1.3 84.5 ± 5.8
Values represent mean ± SD. N = 6 animals/group. Total of 500 cells scored per treatment.
2-AAF: 2-acetamidoﬂuorene.
DMN: dimethylnitrosamine.
Table 13
Unscheduled DNA synthesis (UDS) in rat hepatocytes following oral exposure to a single dose of H-EPG-05 soyate.
Dose (mg/kg bw) Nuclear grain (NG) count Cytoplasmic grain
(CG) count
Net nuclear
grain (NNG) count
Net grain count of
cells in repair
Percent of cells in repair
(i.e., NNGP 5)
12- to 14-h exposure
0 (corn oil) 3.97 ± 0.78 4.26 ± 0.84 0.3 ± 0.5 6.0 ± 0.5 1.8 ± 2.0
632.5 2.68 ± 0.42 3.70 ± 0.54 1.0 ± 0.2 6.0 ± 0 0.2 ± 0.4
2000 2.84 ± 0.68 3.45 ± 0.39 0.6 ± 0.4 0 –
2-AAF (75) 16.83 ± 4.38 5.84 ± 1.95 11.0 ± 3.1 12.3 ± 2.7 84.0 ± 12.9
2- to 4-h exposure
0 (corn oil) 2.35 ± 0.69 3.19 ± 0.40 0.8 ± 0.4 0 –
632.5 2.86 ± 0.80 3.58 ± 1.25 0.7 ± 0.7 0 –
2000 3.04 ± 1.34 3.58 ± 1.42 0.5 ± 0.6 6.0 ± 0.9 0.4 ± 0.5
DMN (10) 12.57 ± 2.18 5.25 ± 3.24 7.3 ± 2.3 10.0 ± 1.4 65.4 ± 15.1
Values represent mean ± SD. N = 6 animals/group. Total of 500 cells scored per treatment.
2-AAF: 2-acetamidoﬂuorene.
DMN: dimethylnitrosamine.
Table 14
Unscheduled DNA synthesis (UDS) in rat hepatocytes following oral exposure to a single dose of H-EPG-14 soyate.
Dose (mg/kg bw) Nuclear grain (NG) count Cytoplasmic grain
(CG) count
Net nuclear
grain (NNG) count
Net grain count
of cells in repair
Percent of cells in repair
(i.e., NNGP 5)
12- to 14-h exposure
0 (corn oil) 3.97 ± 0.78 4.26 ± 0.84 0.3 ± 0.5 6.0 ± 0.5 1.8 ± 2.0
632.5 3.05 ± 0.96 4.98 ± 1.56 1.9 ± 0.8 0 –
2000 3.62 ± 2.33 4.56 ± 2.59 0.9 ± 0.5 9.8 ± 0 1.4 ± 3.1
2-AAF (75) 16.83 ± 4.38 5.84 ± 1.95 11.0 ± 3.1 12.3 ± 2.7 84.0 ± 12.9
2- to 4-h exposure
0 (corn oil) 2.35 ± 0.69 3.19 ± 0.40 0.8 ± 0.4 0 –
632.5 2.89 ± 0.80 3.67 ± 0.85 0.8 ± 0.4 5.7 ± 0.3 0.8 ± 0.8
2000 2.37 ± 0.55 3.34 ± 0.77 1.0 ± 0.6 5.0 ± 0 0.1 ± 0.3
DMN (10) 12.57 ± 2.18 5.25 ± 3.24 7.3 ± 2.3 10.0 ± 1.4 65.4 ± 15.1
Values represent mean ± SD. N = 6 animals/group. Total of 500 cells scored per treatment.
2-AAF: 2-acetamidoﬂuorene.
DMN: dimethylnitrosamine.
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50% of cells responding (i.e., in repair). The criteria for a positive
response were as follows: (1) a population average NNGP 5 and
at least 20% of cells in repair; and (2) a dose-related increase in
both the population average NNG and percentage of cells in repair.3. Results
3.1. Bacterial reverse mutation assay (S. typhimurium and E. coli)
There were no increases in cytotoxicity or the number of histi-
dine revertants per plate observed in S. typhimurium and E. colistrains exposed to H-EPG-05 HR/SO 9:1, H-EPG-05 soyate, or H-
EPG-14 soyate with and without metabolic activation (Tables 1a,
1b, 2a, 2b, 3a and 3b). Under the conditions of this assay, H-EPG-
05 HR/SO 9:1, H-EPG-05 soyate, and H-EPG-14 soyate are not
mutagenic in this system.3.2. Bacterial reverse mutation assay (S. typhimurium)
Heated and unheated versions of H-EPG-05 HR/SO 9:1 and EPG-
05 HR/ST 45:55 (vs. palm/rapeseed oil 60:40 and cottonseed oil,
respectively) did not increase the number of histidine revertants
per plate of S. typhimurium strains TA98 and TA100 exposed in
S142 D.H. Bechtel / Regulatory Toxicology and Pharmacology 70 (2014) S131–S142the presence and absence of a metabolic fraction (Tables 4a, 4b, 5a
and 5b). Under the conditions of this assay, heated and unheated
H-EPG-05 HR/SO 9:1 and EPG-05 HR/ST 45:55 are not mutagenic
in this system.
3.3. In vitro mouse lymphoma TK+/ gene mutation assay
H-EPG-05 HR/SO 9:1, H-EPG-05 soyate, and H-EPG-14 soyate
did not induce mutations in mouse lymphoma L5178Y cells at
any dose level (Tables 6–8, respectively). Under the conditions of
this assay, H-EPG-05 HR/SO 9:1, H-EPG-05 soyate, and H-EPG-14
soyate are not mutagenic in this test system.
3.4. In vitro mammalian chromosomal aberration test
H-EPG-05 HR/SO 9:1, H-EPG-05 soyate, and H-EPG-14 soyate
did not induce a statistically signiﬁcant increases in the incidence
of chromosomal aberrations in cultured human lymphocytes at
any of the concentrations tested, with or without metabolic activa-
tion (Tables 9–11, respectively). Under the conditions of this study,
H-EPG-05 HR/SO 9:1, H-EPG-05 soyate, and H-EPG-14 soyate do
not induce chromosomal aberrations in cultured human
lymphocytes.
3.5. Unscheduled DNA synthesis (UDS) test with mammalian liver cells
in vivo/ex vivo
No signs of toxicity were noted in male Wistar rats receiving a
single oral dose of EPG (H-EPG-05 HR/SO 9:1, H-EPG-05 soyate, or
H-EPG-14 soyate) up to 2000 mg/kg bw. Analysis of hepatocytes
harvested after 12–14 or 2–4 h revealed no UDS induction in these
animals (Table 12–14, respectively). H-EPG-05 HR/SO 9:1, H-EPG-
05 soyate, and H-EPG-14 soyate are not genotoxic in this test sys-
tem under the conditions employed.
4. Discussion
The EPG versions tested, H-EPG-05 HR/SO 9:1, H-EPG-05 soyate,
H-EPG-14 soyate, and EPG-05 HR/ST 45:55, did not exhibit geno-
toxic potential in any of the test systems employed.
No such activity would be expected, however, since EPG con-
tains no structural alerts for genotoxicity (Benigni et al., 2008);that is, EPG contains no molecular functional groups or substruc-
tures that are linked to the genotoxic activity of test materials.
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